Plant Name: Ononis vaginalis
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; NPSR1; CXCR1; NMUR2; | |
| ADRA2C; ADRA2A; DRD4; | |
| ALPL; RECQL; PLA2G1B; TDP1; ALPI; CTDSP1; PIK3R1; GLO1; HPGD; MPO; HSD17B1; AKR1B1; HSD17B2; HSD17B10; ALOX15; HSD17B3; ALDH1A1; ALOX12; NOX4; SENP6; SENP7; PYGL; POLB; | |
| ACHE; GAA; | |
| AKT1; MET; CAMK2B; CSNK2A1; DAPK1; NEK2; FLT3; NEK6; SRC; IGF1R; PTK2; AURKB; GSK3B; CDK1; MAPK1; PIM1; NUAK1; ALK; PDPK1; AXL; KDR; PKN1; | |
| CA12; CA14; CA7; CA3; CA5B; CA1; CA9; CA4; CA6; CA2; CA5A; | |
| AR; | |
| NR1H4; | |
| ESRRA; | |
| ESR1; | |
| KDM4E; | |
| MAOA; ALOX5; TYR; XDH; | |
| MMP13; MMP3; MMP2; MMP9; | |
| BACE1; | |
| AHR; STAT6; HIF1A; NFKB1; TP53; | |
| FUT7; | |
| SLC5A1; SLC5A2; SLC5A4; | |
| ABCC1; ABCG2; | |
| LMNA; MAPT; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 2 | CYP2C8 | Cytochrome P450 2C8 | P10632 | CHEMBL3721 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | ALPI | Intestinal alkaline phosphatase | P09923 | CHEMBL5573 |
| Enzyme_unclassified | CTDSP1 | Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 | Q9GZU7 | CHEMBL1795098 |
| Enzyme_unclassified | PIK3R1 | PI3-kinase p85-alpha subunit | P27986 | CHEMBL2506 |
| Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | MPO | Myeloperoxidase | P05164 | CHEMBL2439 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | HSD17B3 | Estradiol 17-beta-dehydrogenase 3 | P37058 | CHEMBL4234 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | SENP6 | Sentrin-specific protease 6 | Q9GZR1 | CHEMBL1741215 |
| Enzyme_unclassified | SENP7 | Sentrin-specific protease 7 | Q9BQF6 | CHEMBL1741213 |
| Enzyme_unclassified | PYGL | Liver glycogen phosphorylase | P06737 | CHEMBL2568 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP13 | Matrix metalloproteinase 13 | P45452 | CHEMBL280 |
| Metallo protease | MMP3 | Matrix metalloproteinase 3 | P08254 | CHEMBL283 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
| Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Peptide receptor (family A GPCR) | CXCR1 | Interleukin-8 receptor A | P25024 | CHEMBL4029 |
| Peptide receptor (family A GPCR) | NMUR2 | Neuromedin-U receptor 2 | Q9GZQ4 | CHEMBL1075144 |
| Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | CAMK2B | CaM kinase II beta | Q13554 | CHEMBL4121 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
| Protein Kinase | NEK2 | Serine/threonine-protein kinase NEK2 | P51955 | CHEMBL3835 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | NEK6 | Serine/threonine-protein kinase NEK6 | Q9HC98 | CHEMBL4309 |
| Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
| Protein Kinase | ALK | ALK tyrosine kinase receptor | Q9UM73 | CHEMBL4247 |
| Protein Kinase | PDPK1 | 3-phosphoinositide dependent protein kinase-1 | O15530 | CHEMBL2534 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | PKN1 | Protein kinase N1 | Q16512 | CHEMBL3384 |
| SLC superfamily of solute carriers | SLC5A4 | Low affinity sodium-glucose cotransporter | Q9NY91 | CHEMBL1770047 |
| SLC superfamily of solute carriers | SLC5A1 | Sodium/glucose cotransporter 1 | P13866 | CHEMBL4979 |
| SLC superfamily of solute carriers | SLC5A2 | Sodium/glucose cotransporter 2 | P31639 | CHEMBL3884 |
| Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
| Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
| Small molecule receptor (family A GPCR) | DRD4 | Dopamine D4 receptor | P21917 | CHEMBL219 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.405E-12 | 1.093E-09 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, NOX4 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 3.415E-12 | 2.277E-09 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 3.857E-11 | 1.787E-08 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, XDH |
| MF | GO:0005488; binding | GO:0020037; heme binding | 6.016E-11 | 2.471E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, MPO, NOX4, SRC |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 6.762E-10 | 2.017E-07 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 8.428E-10 | 2.447E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 8.715E-10 | 2.497E-07 | ALPI, AR, CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR1, ESRRA, GLO1, MMP13, MMP2, MMP3, MMP9, NR1H4, TP53 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.555E-09 | 4.031E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 2.587E-09 | 6.011E-07 | CYP1A2, CYP2C19, CYP2C8, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0005524; ATP binding | 4.574E-09 | 9.671E-07 | ABCC1, ABCG2, AKT1, ALK, AURKB, AXL, CAMK2B, CDK1, CSNK2A1, DAPK1, FLT3, GSK3B, IGF1R, KDR, MAPK1, MET, NEK2, NEK6, NUAK1, PDPK1, PIM1, PKN1, PTK2, PYGL, RECQL, SRC, TP53 |
| BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 6.755E-09 | 1.375E-06 | AKT1, CAMK2B, CDK1, CSNK2A1, GSK3B, MAPK1, PDPK1, PKN1 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.006E-08 | 1.857E-06 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004674; protein serine/threonine kinase activity | 1.160E-08 | 2.071E-06 | AKT1, ALK, AURKB, CAMK2B, CDK1, CSNK2A1, DAPK1, GSK3B, MAPK1, NEK2, NEK6, NUAK1, PDPK1, PIM1, PKN1 |
| BP | GO:0008152; metabolic process | GO:0018105; peptidyl-serine phosphorylation | 1.406E-08 | 2.417E-06 | AKT1, AURKB, CAMK2B, CDK1, GSK3B, MAPK1, NEK6, PDPK1, PKN1, SRC |
| BP | GO:0009987; cellular process | GO:0030168; platelet activation | 1.031E-07 | 1.448E-05 | ADRA2A, ADRA2C, AKT1, AXL, MAPK1, PDPK1, PIK3R1, SRC |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 2.721E-07 | 3.366E-05 | AURKB, CA2, CA7, HIF1A, MAPK1, NEK2, NPSR1, NR1H4, PDPK1, PLA2G1B |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 3.242E-07 | 3.966E-05 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 5.134E-07 | 6.042E-05 | ABCC1, ALOX12, ALOX15, ALOX5, PLA2G1B |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 6.059E-07 | 6.857E-05 | AHR, CSNK2A1, HIF1A, KDR, MAPT |
| BP | GO:0065007; biological regulation | GO:0032148; activation of protein kinase B activity | 8.304E-07 | 8.952E-05 | ADRA2A, ADRA2C, AKT1, PDPK1, SRC |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 1.036E-06 | 1.085E-04 | ADRA2A, AURKB, CA2, CA7, HIF1A, KDR, MAPK1, NEK2, NPSR1, NR1H4, PDPK1, PLA2G1B, SRC |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 1.173E-06 | 1.217E-04 | ALOX12, ALOX15, ALOX5, HPGD |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 1.336E-06 | 1.360E-04 | CYP1A1, CYP2C8, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 2.041E-06 | 1.933E-04 | AKT1, ALPL, AR, CYP1A1, CYP1B1, ESR1, FLT3, MAPK1, NFKB1, NOX4, SRC |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 2.663E-06 | 2.467E-04 | CYP1A1, CYP2C8, CYP3A4 |
| MF | GO:0005215; transporter activity | GO:0005412; glucose:sodium symporter activity | 2.663E-06 | 2.467E-04 | SLC5A1, SLC5A2, SLC5A4 |
| BP | Unclassified; | GO:0015758; glucose transport | 3.895E-06 | 3.483E-04 | AKT1, PLA2G1B, SLC5A1, SLC5A2, SLC5A4 |
| MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 5.352E-06 | 4.606E-04 | AHR, AR, ESR1, ESRRA, NR1H4 |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 5.568E-06 | 4.754E-04 | AR, CYP3A4, ESR1, ESRRA, HSD17B1, NR1H4 |
| MF | GO:0005488; binding | GO:0051379; epinephrine binding | 7.399E-06 | 6.103E-04 | ADRA2A, ADRA2C, DRD4 |
| MF | GO:0005488; binding | GO:0019901; protein kinase binding | 8.844E-06 | 7.185E-04 | ADRA2A, AKT1, ESR1, GSK3B, HIF1A, MAPK1, NEK6, PDPK1, PIK3R1, PKN1, PTK2, SRC, TP53 |
| MF | GO:0005488; binding | GO:0032052; bile acid binding | 1.106E-05 | 8.787E-04 | NR1H4, PLA2G1B, PYGL |
| CC | GO:0043226; organelle | GO:0043227; membrane-bounded organelle | 1.194E-05 | 9.420E-04 | ABCC1, ABCG2, ACHE, ADRA2C, AHR, AKR1B1, AKT1, ALDH1A1, ALK, ALOX12, ALPL, AR, AURKB, AXL, BACE1, CA1, CA2, CA4, CA5A, CA5B, CA6, CDK1, CSNK2A1, CTDSP1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, ESR1, ESRRA, FLT3, FUT7, GAA, GLO1, GSK3B, HIF1A, HPGD, HSD17B10, HSD17B3, IGF1R, KDM4E, KDR, LMNA, MAOA, MAPK1, MAPT, MMP2, MMP9, MPO, NEK6, NFKB1, NOX4, NUAK1, PDPK1, PIK3R1, PIM1, PKN1, PLA2G1B, POLB, PTK2, PYGL, RECQL, SENP7, SLC5A1, SLC5A2, SRC, TDP1, TP53, TYR, XDH |
| BP | GO:0008152; metabolic process | GO:0008209; androgen metabolic process | 1.258E-05 | 9.875E-04 | CYP19A1, CYP3A4, ESR1, HSD17B3 |
| BP | GO:0050896; response to stimulus | GO:0032496; response to lipopolysaccharide | 1.372E-05 | 1.059E-03 | ALPL, AXL, CYP1A1, CYP1A2, HPGD, MPO, NFKB1, NR1H4, SRC |
| BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 1.590E-05 | 1.210E-03 | AKR1B1, AXL, CDK1, CYP1B1, STAT6 |
| BP | GO:0009987; cellular process | GO:0010638; positive regulation of organelle organization | 1.736E-05 | 1.308E-03 | ALOX15, AURKB, GSK3B, HIF1A, KDR, MAPK1, MAPT, MET, MMP9, NEK2, NOX4, SRC, TP53 |
| BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 1.859E-05 | 1.372E-03 | HIF1A, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
| BP | GO:0065007; biological regulation | GO:0042593; glucose homeostasis | 1.891E-05 | 1.387E-03 | ADRA2A, AKT1, HIF1A, NOX4, NR1H4, PIK3R1, PYGL |
| BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 1.911E-05 | 1.392E-03 | AKT1, CYP1A2, MAPK1, MMP9 |
| BP | GO:0032501; multicellular organismal process | GO:0060736; prostate gland growth | 2.156E-05 | 1.534E-03 | AR, CYP19A1, ESR1 |
| BP | GO:0009987; cellular process | GO:0031334; positive regulation of protein complex assembly | 2.219E-05 | 1.564E-03 | ALOX15, ESR1, GSK3B, MAPT, MET, MMP3, SRC, TP53 |
| BP | GO:0032502; developmental process | GO:0051094; positive regulation of developmental process | 2.317E-05 | 1.618E-03 | ADRA2C, AKT1, ALOX12, AR, AXL, CA2, CAMK2B, CDK1, CYP1B1, HIF1A, KDR, LMNA, MAPT, NFKB1, NR1H4, PDPK1, PIM1, SRC, STAT6 |
| BP | GO:0051179; localization | GO:0046903; secretion | 2.450E-05 | 1.705E-03 | ALOX5, AXL, CA2, CA9, CXCR1, DRD4, GAA, HIF1A, MAPK1, MMP9, MPO, NFKB1, NMUR2, NR1H4, PLA2G1B, PYGL, XDH |
| BP | GO:0002376; immune system process | GO:0048534; hematopoietic or lymphoid organ development | 2.595E-05 | 1.794E-03 | FLT3, HIF1A, KDR, MAPK1, PKN1, POLB, TYR |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 2.654E-05 | 1.806E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 2.654E-05 | 1.806E-03 | ALOX12, ALOX15 |
| BP | GO:0032502; developmental process | GO:0007568; aging | 2.680E-05 | 1.818E-03 | AKT1, AURKB, CDK1, CYP1A1, MPO, NOX4, POLB, TP53 |
| BP | GO:0065007; biological regulation | GO:0098771; inorganic ion homeostasis | 2.719E-05 | 1.838E-03 | ABCG2, CA12, CA2, CA7, DRD4, ESR1, HIF1A, MAPK1, NMUR2, NPSR1, PDPK1, PLA2G1B, TP53 |
| BP | GO:0008283; cell proliferation | GO:0033598; mammary gland epithelial cell proliferation | 2.863E-05 | 1.930E-03 | ESR1, MAPK1, STAT6 |
| BP | GO:0032501; multicellular organismal process | GO:2000026; regulation of multicellular organismal development | 2.994E-05 | 2.006E-03 | ADRA2C, AKT1, ALOX12, AR, AXL, CA2, CAMK2B, CDK1, CTDSP1, CYP1B1, ESR1, ESRRA, GSK3B, HIF1A, KDR, MAPT, NR1H4, PDPK1, PIK3R1, PIM1, PTK2, SRC, STAT6, XDH |
| BP | GO:0065007; biological regulation | GO:0051090; regulation of DNA binding transcription factor activity | 3.307E-05 | 2.195E-03 | AKT1, ALK, AR, CYP1B1, ESR1, MAPK1, NFKB1, NR1H4, PIM1, PLA2G1B |
| BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 3.502E-05 | 2.318E-03 | AHR, AR, ESR1, ESRRA, NR1H4, PIM1, SRC |
| BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 3.574E-05 | 2.342E-03 | AXL, KDR, PIK3R1, PTK2, SRC |
| BP | GO:0065007; biological regulation | GO:0030003; cellular cation homeostasis | 3.647E-05 | 2.378E-03 | ABCG2, CA2, CA7, DRD4, ESR1, HIF1A, MAPK1, NMUR2, NPSR1, PDPK1, PLA2G1B, TP53 |
| BP | GO:0008152; metabolic process | GO:0006703; estrogen biosynthetic process | 3.708E-05 | 2.403E-03 | CYP19A1, HSD17B1, HSD17B2 |
| BP | Unclassified; | GO:0044243; multicellular organismal catabolic process | 3.821E-05 | 2.469E-03 | MMP13, MMP2, MMP3, MMP9, PLA2G1B |
| BP | GO:0009987; cellular process | GO:0045742; positive regulation of epidermal growth factor receptor signaling pathway | 3.917E-05 | 2.509E-03 | ADRA2A, ADRA2C, AKT1, MMP9 |
| MF | GO:0005488; binding | GO:0001221; transcription cofactor binding | 3.917E-05 | 2.509E-03 | AHR, ESR1, NEK6, TP53 |
| BP | GO:0009987; cellular process | GO:1903201; regulation of oxidative stress-induced cell death | 4.082E-05 | 2.599E-03 | AKT1, HIF1A, MET, MMP3, TP53 |
| BP | GO:0032502; developmental process | GO:0060065; uterus development | 4.702E-05 | 2.951E-03 | CYP19A1, ESR1, SRC |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 5.161E-05 | 3.202E-03 | ABCC1, ADRA2A, CA2, CA4, CA9, HPGD, TSHR |
| BP | GO:0032501; multicellular organismal process | GO:0043536; positive regulation of blood vessel endothelial cell migration | 7.831E-05 | 4.577E-03 | AKT1, HIF1A, KDR, PDPK1 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 7.934E-05 | 4.577E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 7.934E-05 | 4.577E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 7.934E-05 | 4.577E-03 | ALOX12, ALOX15 |
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 7.934E-05 | 4.577E-03 | ADRA2A, ADRA2C |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 7.934E-05 | 4.577E-03 | ALOX12, ALOX15 |
| BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 8.402E-05 | 4.815E-03 | HIF1A, MMP13, MMP2, MMP3, MMP9 |
| BP | GO:0009987; cellular process | GO:0090199; regulation of release of cytochrome c from mitochondria | 8.560E-05 | 4.892E-03 | AKT1, LMNA, MMP9, TP53 |
| BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 8.685E-05 | 4.912E-03 | AURKB, MAPK1, NEK2 |
| MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 8.685E-05 | 4.912E-03 | CYP2C19, CYP2C8, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0035173; histone kinase activity | 8.685E-05 | 4.912E-03 | AURKB, CDK1, PKN1 |
| BP | GO:0008152; metabolic process | GO:0044283; small molecule biosynthetic process | 9.276E-05 | 5.206E-03 | AKR1B1, ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP3A4, HSD17B3, MPO, PLA2G1B |
| BP | GO:0065007; biological regulation | GO:0000187; activation of MAPK activity | 9.977E-05 | 5.528E-03 | ALK, CDK1, DRD4, MAPK1, PKN1, PLA2G1B |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 1.017E-04 | 5.605E-03 | IGF1R, KDR, PTK2, SRC |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 1.042E-04 | 5.707E-03 | CA2, CA7, KDR, NPSR1, PDPK1, PLA2G1B, SRC |
| BP | GO:0008152; metabolic process | GO:2000379; positive regulation of reactive oxygen species metabolic process | 1.043E-04 | 5.707E-03 | AKT1, MAPT, NOX4, TP53, XDH |
| BP | GO:0048511; rhythmic process | GO:0048511; rhythmic process | 1.144E-04 | 6.166E-03 | AHR, AXL, CSNK2A1, DRD4, ESR1, GSK3B, SRC, TP53 |
| MF | Unclassified; | GO:0004872; receptor activity | 1.200E-04 | 6.433E-03 | ADRA2A, ADRA2C, AHR, ALK, AR, AXL, CXCR1, DRD4, ESR1, ESRRA, FLT3, HPGD, IGF1R, KDR, MET, NMUR2, NPSR1, NR1H4, SENP7, TSHR |
| BP | GO:0008152; metabolic process | GO:1901575; organic substance catabolic process | 1.232E-04 | 6.558E-03 | ACHE, AKT1, ALDH1A1, AURKB, BACE1, CDK1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4, FUT7, GAA, GSK3B, HSD17B10, MAOA, PLA2G1B, PYGL, TP53, XDH |
| CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 1.352E-04 | 7.145E-03 | AHR, AKR1B1, AKT1, ALOX5, AR, AURKB, CAMK2B, CDK1, CSNK2A1, CTDSP1, ESR1, ESRRA, GSK3B, HIF1A, HPGD, LMNA, MAPK1, NEK2, NEK6, NFKB1, NR1H4, NUAK1, PDPK1, PIM1, PKN1, POLB, RECQL, SENP6, SRC, STAT6, TP53 |
| BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 1.395E-04 | 7.331E-03 | AXL, MET, NOX4, PIK3R1, PTK2, SRC |
| BP | GO:0065007; biological regulation | GO:0032431; activation of phospholipase A2 activity | 1.581E-04 | 8.083E-03 | NMUR2, PLA2G1B |
| BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 1.581E-04 | 8.083E-03 | ADRA2A, ADRA2C |
| BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 1.581E-04 | 8.083E-03 | ADRA2A, ADRA2C |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.581E-04 | 8.083E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0005497; androgen binding | 1.581E-04 | 8.083E-03 | ALDH1A1, AR |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 1.673E-04 | 8.415E-03 | CYP1A1, POLB, TP53 |
| BP | GO:0008152; metabolic process | GO:0005977; glycogen metabolic process | 1.753E-04 | 8.757E-03 | AKT1, GAA, GSK3B, PYGL |
| BP | Unclassified; | GO:0035428; hexose transmembrane transport | 1.930E-04 | 9.445E-03 | SLC5A1, SLC5A2, SLC5A4 |
| BP | GO:0051179; localization | GO:1904659; glucose transmembrane transport | 1.930E-04 | 9.445E-03 | SLC5A1, SLC5A2, SLC5A4 |
| BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 1.930E-04 | 9.445E-03 | HPGD, MMP2, MMP9 |
| BP | Unclassified; | GO:1905950; monosaccharide transmembrane transport | 1.930E-04 | 9.445E-03 | SLC5A1, SLC5A2, SLC5A4 |
| BP | GO:0051179; localization | GO:0051222; positive regulation of protein transport | 1.952E-04 | 9.529E-03 | ACHE, CDK1, GSK3B, HIF1A, MAPK1, NR1H4, PIK3R1, PLA2G1B, SRC, TP53 |
| BP | GO:0022610; biological adhesion | GO:0001952; regulation of cell-matrix adhesion | 1.970E-04 | 9.578E-03 | GSK3B, KDR, PIK3R1, PTK2, SRC |
| BP | GO:0009987; cellular process | GO:2001237; negative regulation of extrinsic apoptotic signaling pathway | 1.970E-04 | 9.578E-03 | AKT1, AR, DAPK1, LMNA, SRC |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 2.062E-04 | 9.976E-03 | AKT1, HIF1A, LMNA, SRC, TP53 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 5.448E-23 | 5.931E-19 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.707E-16 | 5.895E-13 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.982E-15 | 3.923E-12 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 3.343E-22 | 6.318E-20 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 8.823E-14 | 8.338E-12 | CAMK2B; PDPK1; SRC; MMP2; PIK3R1; HIF1A; ESR1; MMP9; PTK2; IGF1R; KDR; AKT1; MAPK1; TP53; MET |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.229E-09 | 3.636E-08 | GSK3B; FLT3; DAPK1; MMP2; PIK3R1; HIF1A; MMP9; NFKB1; PTK2; IGF1R; AR; AKT1; MAPK1; MET; TP53 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 6.181E-10 | 2.337E-08 | GSK3B; AR; PDPK1; AKT1; MAPK1; PIK3R1; TP53; NFKB1; IGF1R |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 1.347E-09 | 3.636E-08 | PLA2G1B; MAOA; ALOX15; HSD17B3; AKR1B1; ALOX12; PYGL; CYP2C19; CYP3A4; CYP19A1; HSD17B10; FUT7; HSD17B1; ALOX5; HSD17B2; XDH; GAA; TYR; CYP2C9; CYP2C8; CYP1A2; ALDH1A1; CYP1A1; ALPL; ALPI |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 9.003E-11 | 5.672E-09 | CYP2C9; CYP2C8; PLA2G1B; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 4.583E-10 | 2.166E-08 | HSD17B1; CYP1A2; HSD17B2; CYP1A1; HSD17B3; CYP1B1; CYP3A4; CYP19A1 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 5.289E-09 | 1.250E-07 | HSD17B1; ALOX5; HSD17B2; CYP1A1; CYP1B1; CYP19A1; IGF1R |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 7.719E-09 | 1.621E-07 | GSK3B; PDPK1; SRC; AKT1; MAPK1; PIK3R1; TP53; ESR1; HIF1A |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 2.480E-08 | 4.261E-07 | CYP2C9; CYP2C8; PLA2G1B; ALOX5; ALOX15; ALOX12; CYP2C19 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 2.334E-08 | 4.261E-07 | HPGD; FLT3; MMP3; TP53; MPO; MMP9; MET; NFKB1; PTK2; IGF1R |
| hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 6.948E-08 | 8.986E-07 | GSK3B; PDPK1; SRC; KDR; AKT1; MAPK1; PIK3R1; MET; PTK2; IGF1R |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 1.364E-07 | 1.516E-06 | GSK3B; PDPK1; KDR; AKT1; MAPK1; PIK3R1; PKN1; TP53; MET; PTK2; NFKB1; IGF1R |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 4.297E-08 | 6.767E-07 | FLT3; AKT1; MAPK1; PIK3R1; TP53; MET; HIF1A |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 7.132E-08 | 8.986E-07 | GSK3B; SRC; AKT1; MAPK1; PIK3R1; ESR1; NFKB1 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 9.114E-08 | 1.077E-06 | CYP2C9; CYP2C8; MAOA; ALOX5; ALOX15; MAPK1; ALOX12; CYP2C19 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 1.559E-07 | 1.637E-06 | CAMK2B; GSK3B; PDPK1; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 5.240E-08 | 7.618E-07 | DAPK1; SRC; MMP2; MAPK1; MMP9; TP53 |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 2.661E-07 | 2.395E-06 | CAMK2B; GSK3B; SRC; AKT1; MAPK1; PIK3R1; PTK2 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 7.025E-07 | 5.107E-06 | SRC; AKT1; MAPK1; STAT6; PIK3R1; TP53; MMP9; NFKB1 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 2.269E-07 | 2.145E-06 | GSK3B; PDPK1; AKT1; MAPK1; PIK3R1; TP53 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 3.562E-07 | 3.060E-06 | ALK; PDPK1; AKT1; MAPK1; PIK3R1; TP53 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.767E-07 | 1.758E-06 | CYP2C9; CYP2C8; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 6.457E-07 | 4.881E-06 | SRC; MMP2; AKT1; MAPK1; PIK3R1; ESR1; MMP9 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 3.965E-07 | 3.258E-06 | FLT3; PIM1; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 5.969E-07 | 4.701E-06 | SRC; KDR; AKT1; MAPK1; PIK3R1; PTK2 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 8.455E-07 | 5.695E-06 | CAMK2B; AKT1; MAPK1; PIK3R1; HIF1A; NFKB1; IGF1R |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 8.738E-07 | 5.695E-06 | CAMK2B; AKT1; MAPK1; PIK3R1; TP53; IGF1R |
| hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 4.493E-06 | 2.573E-05 | GSK3B; CXCR1; SRC; AKT1; MAPK1; PIK3R1; NFKB1; PTK2 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 6.593E-06 | 3.560E-05 | PDPK1; LMNA; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 2.369E-06 | 1.399E-05 | ABCC1; PDPK1; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 1.479E-06 | 9.017E-06 | AKT1; MAPK1; PIK3R1; TP53; MET; IGF1R |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 4.698E-06 | 2.612E-05 | GSK3B; PDPK1; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 1.160E-05 | 6.089E-05 | MMP2; PIM1; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 8.738E-07 | 5.695E-06 | CYP2C9; CYP2C8; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.248E-06 | 7.862E-06 | CYP2C9; CYP2C8; MAOA; CYP1A2; CYP3A4; CYP2C19 |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 1.848E-05 | 8.508E-05 | PLA2G1B; KDR; AKT1; MAPK1; PIK3R1; MET; NFKB1; IGF1R |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 1.372E-05 | 6.824E-05 | GSK3B; PDPK1; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 1.795E-05 | 8.480E-05 | GSK3B; PDPK1; AKT1; PIK3R1; PYGL; NFKB1 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 1.891E-05 | 8.508E-05 | MMP3; AKT1; MAPK1; PIK3R1; MMP9; NFKB1 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 2.817E-05 | 1.164E-04 | PDPK1; ALOX5; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 1.241E-05 | 6.338E-05 | PDPK1; AKT1; MAPK1; PIK3R1; HIF1A |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 6.995E-05 | 2.454E-04 | GSK3B; CSNK2A1; CDK1; AKT1; PIK3R1; TP53; NFKB1 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 1.459E-05 | 7.069E-05 | GSK3B; AKT1; MAPK1; PIK3R1; TP53 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 6.249E-05 | 2.271E-04 | GSK3B; CSNK2A1; AKT1; PIK3R1; TP53; NFKB1 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 7.674E-05 | 2.590E-04 | POLB; SRC; CDK1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 9.193E-05 | 3.048E-04 | SRC; KDR; AKT1; MAPK1; PIK3R1; MET; IGF1R |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 1.983E-05 | 8.517E-05 | AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 1.228E-04 | 3.934E-04 | ABCC1; PIM1; CYP1B1; MAPK1; TP53; MMP9; MET; NFKB1 |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 7.055E-05 | 2.454E-04 | GSK3B; PDPK1; AKT1; MAPK1; PIK3R1; PYGL |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 3.242E-05 | 1.250E-04 | AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 1.983E-05 | 8.517E-05 | AKT1; MAPK1; PIK3R1; MET; HIF1A |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 3.242E-05 | 1.250E-04 | GSK3B; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 3.242E-05 | 1.250E-04 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 2.381E-04 | 7.259E-04 | CAMK2B; ACHE; AKT1; MAPK1; PIK3R1 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 2.832E-05 | 1.164E-04 | CA2; NR1H4; SLC5A1; CYP3A4; ABCG2 |
| hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 1.328E-04 | 4.183E-04 | CDK1; AKT1; MAPK1; PIK3R1; IGF1R |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 1.091E-04 | 3.554E-04 | AKT1; PIK3R1; TP53; NFKB1; IGF1R |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 3.463E-05 | 1.309E-04 | CSNK2A1; SRC; MAPK1; MET; IGF1R |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 1.531E-04 | 4.743E-04 | PDPK1; AKT1; MAPK1; PIK3R1; HIF1A |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 7.141E-05 | 2.454E-04 | AKT1; PIK3R1; TP53; NFKB1; PTK2 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 4.938E-04 | 1.372E-03 | CAMK2B; AKT1; MAPK1; PIK3R1; NFKB1; TSHR |
| hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 3.830E-04 | 1.097E-03 | CAMK2B; AR; CDK1; MAPK1; IGF1R |
| hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 4.765E-04 | 1.344E-03 | CAMK2B; GSK3B; MAOA; AKT1; DRD4 |
| hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 5.477E-04 | 1.500E-03 | PDPK1; AKT1; MAPK1; PIK3R1; IGF1R |
| hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 7.371E-04 | 1.962E-03 | GSK3B; AKT1; MAPK1; PIK3R1; IGF1R |
| hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 1.520E-03 | 3.779E-03 | AKT1; MAPK1; PIK3R1; ADRA2C; ADRA2A |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 1.886E-03 | 4.400E-03 | POLB; GSK3B; AKT1; PIK3R1; TP53; NFKB1 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 1.560E-03 | 3.829E-03 | BACE1; GSK3B; MAPK1; MAPT; HSD17B10 |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 1.866E-03 | 4.400E-03 | GSK3B; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 1.483E-03 | 3.738E-03 | CAMK2B; SRC; ALOX12; PIK3R1 |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 1.127E-03 | 2.918E-03 | CAMK2B; SRC; MMP2; MAPK1 |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 2.010E-03 | 4.577E-03 | CAMK2B; SRC; AKT1; MAPK1; NFKB1 |
| hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 3.749E-04 | 1.090E-03 | PDPK1; AKT1; MAPK1; PIK3R1 |
| hsa04916 | Melanogenesis_Homo sapiens_hsa04916 | 1.598E-03 | 3.872E-03 | CAMK2B; GSK3B; MAPK1; TYR |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 1.846E-03 | 4.400E-03 | AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 1.979E-03 | 4.561E-03 | AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 3.293E-03 | 7.153E-03 | SRC; AKT1; MAPK1; PIK3R1 |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 5.642E-03 | 1.147E-02 | CAMK2B; GSK3B; CSNK2A1; TP53 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 9.140E-03 | 1.705E-02 | AKT1; MAPK1; MAPT; TP53; NFKB1 |
| hsa04152 | AMPK signaling pathway_Homo sapiens_hsa04152 | 3.490E-03 | 7.496E-03 | PDPK1; AKT1; PIK3R1; IGF1R |
| hsa04144 | Endocytosis_Homo sapiens_hsa04144 | 9.734E-03 | 1.769E-02 | CXCR1; SRC; KDR; MET; IGF1R |
| hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 5.926E-03 | 1.179E-02 | CXCR1; AKT1; MAPK1; PIK3R1 |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 6.991E-03 | 1.362E-02 | GSK3B; AKT1; PIK3R1; NFKB1 |
| hsa04261 | Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | 6.520E-03 | 1.284E-02 | CAMK2B; AKT1; MAPK1; PIK3R1 |
| hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 2.921E-03 | 6.419E-03 | MMP2; PIK3R1; MMP9; PTK2 |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 4.361E-03 | 8.959E-03 | AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 8.177E-03 | 1.561E-02 | PIM1; AKT1; STAT6; PIK3R1 |
| hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 3.802E-03 | 8.073E-03 | GSK3B; MAPK1; MET; PTK2 |
| hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 8.177E-03 | 1.561E-02 | CAMK2B; SRC; MAPK1; PIK3R1 |
| hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 6.321E-04 | 1.707E-03 | SRC; PIK3R1; MET; PTK2 |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 1.273E-02 | 2.249E-02 | NMUR2; ADRA2C; ADRA2A; DRD4; TSHR |
| hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 3.749E-04 | 1.090E-03 | CXCR1; SRC; MET; NFKB1 |
| hsa04810 | Regulation of actin cytoskeleton_Homo sapiens_hsa04810 | 2.253E-02 | 3.735E-02 | SRC; MAPK1; PIK3R1; PTK2 |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 1.396E-02 | 2.399E-02 | CSNK2A1; CDK1; TP53; NFKB1 |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 2.434E-02 | 3.966E-02 | GSK3B; CDK1; TP53 |
| hsa04922 | Glucagon signaling pathway_Homo sapiens_hsa04922 | 1.419E-02 | 2.417E-02 | CAMK2B; AKT1; PYGL |
| hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 1.382E-02 | 2.397E-02 | PIK3R1; NFKB1; PTK2 |
| hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 1.137E-02 | 2.028E-02 | AKT1; MAPK1; PIK3R1 |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 9.791E-03 | 1.769E-02 | SRC; CDK1; MAPK1 |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 9.197E-03 | 1.705E-02 | MAPK1; PKN1; NFKB1 |
| hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 4.052E-03 | 8.509E-03 | AKT1; PIK3R1; IGF1R |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 2.775E-03 | 6.169E-03 | AKT1; PIK3R1; TSHR |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 4.233E-03 | 8.791E-03 | SRC; MAPK1; NFKB1 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 4.683E-05 | 1.735E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
| hsa04973 | Carbohydrate digestion and absorption_Homo sapiens_hsa04973 | 1.478E-03 | 3.738E-03 | AKT1; PIK3R1; SLC5A1 |
| hsa05217 | Basal cell carcinoma_Homo sapiens_hsa05217 | 3.096E-02 | 4.958E-02 | GSK3B; TP53 |
| hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 9.727E-04 | 2.553E-03 | PDPK1; MAPK1; PIK3R1 |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 2.499E-02 | 4.037E-02 | MAOA; NFKB1 |
| hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 2.405E-02 | 3.952E-02 | MAPK1; PIK3R1 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 2.221E-02 | 3.714E-02 | CYP3A4; XDH |
| hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 2.043E-02 | 3.448E-02 | ABCC1; ABCG2 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 9.203E-03 | 1.705E-02 | MAPK1; TP53 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 9.829E-03 | 1.769E-02 | GAA; AKR1B1 |
| hsa00350 | Tyrosine metabolism_Homo sapiens_hsa00350 | 1.323E-02 | 2.315E-02 | MAOA; TYR |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 5.848E-03 | 1.176E-02 | CA2; CA4 |
| hsa00790 | Folate biosynthesis_Homo sapiens_hsa00790 | 2.166E-03 | 4.873E-03 | ALPL; ALPI |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 2.451E-04 | 7.353E-04 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
| C00-D49: Neoplasms | Colon cancer | C50 | ALPL; FLT3 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; IGF1R; MMP9; TP53; KDR |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | SLC5A2; MET |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | AKT1; CA9; HIF1A; PDPK1 |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Corneal ulcers | H16.0 | MMP3 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR; ESR1 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | AKT1; FLT3; ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PTK2; TP53 |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR |
| C00-D49: Neoplasms | Melanoma | C43 | TYR; KDR; KDR |
| NA: NA | Menopausal disorder | NA | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; KDR |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; ADRA2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C |
| NA: NA | Male hypogonadism | NA | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
| C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | FLT3; FLT3; AURKB; TP53; TP53 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B; ALOX5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
| C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; KDR; KDR; KDR; KDR |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; GSK3B |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; SRC; ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; KDR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Infections disease | A00-B99 | MPO |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | MMP3 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
| C00-D49: Neoplasms | Mesothelioma | C45 | PTK2 |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | AKT1; FLT3; MMP2; KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; MMP13; ACHE; IGF1R; CDK1; ADRA2C; ADRA2A; ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MPO; MAOA; ACHE |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR; ESR1 |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | SLC5A1; SLC5A2; SLC5A2; SLC5A4; NFKB1 |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; IGF1R; AXL; KDR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
| C00-D49: Neoplasms | Multiple myeloma | C90 | AHR; SRC; IGF1R |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | MPO; ESR1; ESR1 |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA; DRD4 |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA4; CA2 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1 |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; SRC |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP13; MMP3; MMP2 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B; ESRRA; ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; MAPT; ACHE; ACHE; ACHE; GSK3B; ADRA2C |
| L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
| C00-D49: Neoplasms | AML | NA | FLT3; KDR |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; ACHE |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ADRA2C; NPSR1; ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA |
| K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ESRRA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2; KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | ESRRA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | ADRA2C |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA; TYR |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CAMK2B; MAOA; ACHE; CYP3A4 |
| A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA; ADRA2C |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR; ESRRA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | SLC5A1; SLC5A2; AKR1B1; SLC5A4; GSK3B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ESRRA; ALOX5 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA; ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR; KDR |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| C00-D49: Neoplasms | Cancer | C00-C96 | AR; AKT1; MET; CSNK2A1; CA1; FLT3; FLT3; CA9; MMP2; ACHE; SRC; IGF1R; PTK2; GSK3B; HIF1A; CDK1; MAPK1; MMP9; NFKB1; PIM1; PDPK1; TP53; ESR1; ESR1; KDR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR; ESRRA |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SRC |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | AKT1; MET; FLT3; CA9; MMP2; SRC; IGF1R; PTK2; AURKB; HIF1A; MAPK1; MMP9; TP53; KDR; KDR; KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PLA2G1B; ESRRA; ALOX5; ALOX5; ADRA2C |
| I00-I99: Diseases of the circulatory system | Ischemic stroke | I61-I63 | MMP3 |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B; ABCC1; ESRRA; ALOX5 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR; KDR |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; CA1; CA1; ACHE; ADRA2C |
| NA: NA | GIST | NA | FLT3 |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | SRC |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioma | C71 | KDR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; ABCC1; ABCC1; XDH |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | DRD4 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
| C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1 |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
| NA: NA | Edema | NA | CA2 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1 |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | SRC; ESR1 |
| C00-D49: Neoplasms | Breast cancer | C50 | AR; CYP19A1; FLT3; FLT3; CA9; IGF1R; CDK1; ESR1; ESR1; KDR; KDR; KDR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; XDH; ADRA2C |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; TP53; KDR; KDR |
| A00-B99: Certain infectious and parasitic diseases | HCV infection | B17.1, B18.2 | MMP3 |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CAMK2B; AKR1B1; PLA2G1B; ESRRA; ALOX5; MMP3; TYR |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA1; CA2 |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MPO; ALOX5 |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SRC; AURKB; TP53 |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1 |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; KDR |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; KDR; KDR |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; IGF1R; ESR1; ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; ESRRA; MMP2; ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD4 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | ADRA2C; CA4; CA4 |
| NA: NA | HIV infections | NA | AHR |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
| H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1 |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA2C |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B; ALOX5 |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; FLT3; ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | SLC5A2 |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | SLC5A4 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MPO; PLA2G1B; ALOX5; MMP13 |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |